Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: A randomized, controlled phase 3 trial

Diabetes, Obesity and Metabolism

Volumn 15, Issue 9, 2013, Pages 826-832

  Onishi, Y ^a   Ono, Y ^b   Rabol R ^c   Endahl, L ^c   Nakamura, S ^d  

^a INSTITUTE FOR ADULT DISEASES   (Japan)

^b Takagi Hospital   (Japan)

^c NOVO NORDISK A S   (Denmark)

^d Heiwadai Hospital   (Japan)

Author keywords

Diabetes mellitus; Glycaemic control; Insulin analogues; Insulin therapy; Phase 3 study

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART PLUS INSULIN DEGLUDEC; INSULIN GLARGINE; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC RETINOPATHY; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPOGLYCEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MEAL; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS;

DIABETES MELLITUS; GLYCAEMIC CONTROL; INSULIN ANALOGUES; INSULIN THERAPY; PHASE 3 STUDY;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84880815448     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12097     Document Type: Article

References (19)

1. Chan JC, Malik V, Jia W et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009; 301: 2129-2140.
2. Kawamori R. Diabetes trends in Japan. Diabetes Metab Res Rev 2002; 18: 9-13.
3. International Diabetes Federation. IDF Diabetes Atlas. Brussels: International Diabetes Federation, 2011.
4. Evans M, Schumm-Draeger PM, Vora J, King AB. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obes Metab 2011; 13: 677-684.
5. Jonassen I, Hoeg-Jensen T, Havelund S, Ribel U. Ultra-long acting insulin degludec can be combined with rapid-acting insulin aspart in a soluble co-formulation. J Pept Sci 2010; 16(S2): 32.
6. Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012; 14: 944-950.
7. Jonassen I, Havelund S, Hoeg-Jensen T et al. Design of the novel protraction mechanism of insulin Degludec, an ultra-long-acting basal insulin. Pharm Res 2012; 29: 2104-2114.
8. Heise T, Hermanski L, Nosek L et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012; 14: 859-864.
9. Birkeland KI, Home PD, Wendisch U et al. Insulin Degludec in type 1 diabetes a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011; 34: 661-665.
10. Garber AJ, King AB, Del PS et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1498-1507.
11. Heller S, Buse J, Fisher M et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1489-1497.
12. World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects - Last amended by the 59th WMA General Assembly, Seoul, 2008.
13. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6 (R1), Step 4, 1996.
14. American Diabetes Association (ADA). Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245-1249.
15. Food and Drug Administration. Food and Drug Administration, Code of Federal Regulations, Guidance for Industry, Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention. Draft Guidance, 2008.
16. Strange P. Treat-to-target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes. J Diabetes Sci Technol 2007; 1: 540-548.
17. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-885.
18. Rodriguez-Fontal M, Kerrison JB, Alfaro DV, Jablon EP. Metabolic control and diabetic retinopathy. Curr Diabetes Rev 2009; 5: 3-7.
19. Fukuda M. Classification and treatment of diabetic retinopathy. Diabetes Res Clin Pract 1994; 24: S171-176.